2026 Third Quarter — Legislative Wrap Up

Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use …

Statement on DEA attempt to reschedule five tryptamines

Last week, the DEA moved to place five little-known psychedelic compounds — 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT — into Schedule I of the Controlled Substances Act. It’s the …

2026 Second Quarter — Policy & Advocacy Wrap Up

Policy & Advocacy Updates This quarter marked an exciting period of growth and progress for MAPS’ Policy & Advocacy team. Through strategic partnerships, innovative research, coalition building, …

PSIP Literature Review

As psychedelics enter the mainstream, new questions arise about how care models can serve diverse populations. To date, research has largely focused on veterans, first responders, and survivors of sexualized …

2026 First Quarter — Legislative Wrap Up

2026 is an important year for psychedelic state policy reform, reflecting the emerging evidence, creative leadership, and increasing confidence of a more mature movement. As the public deepens its understanding …